Last quarter (Q4 2022), Zelira Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Zelira Therapeutics's net income was $―. See Zelira Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	$ ―	$ 1.54M	$ 432.57K	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ 939.05K	$ 228.22K	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 601.57K	$ 204.35K	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 14.25M	$ 10.20M	$ 7.94M	$ 4.24M	$ 2.83M
Operating Income	$ ―	$ -13.65M	$ -9.99M	$ -7.94M	$ -4.24M	$ -2.83M
Net Non Operating Interest Income Expense	$ ―	$ -43.25K	$ -41.90K	$ -3.74K	$ 90.14K	$ 138.57K
Other Income Expense	$ ―	$ 1.28M	$ 1.48M	$ 925.49K	$ 580.44K	$ 959.82K
Pretax Income	$ ―	$ -12.41M	$ -8.55M	$ -7.02M	$ -3.57M	$ -1.73M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -11.95M	$ -8.55M	$ -7.02M	$ -3.57M	$ -1.73M
Basic EPS	$ ―	$ -1.54	$ -1.28	$ -1.45	$ >-0.01	$ ―
Diluted EPS	$ ―	$ -1.54	$ -1.28	$ -1.45	$ >-0.01	$ ―
Basic Average Shares	$ ―	$ 8.04M	$ 6.63M	$ 4.85M	$ 755.07M	$ ―
Diluted Average Shares	$ ―	$ 8.04M	$ 6.63M	$ 4.85M	$ 755.07M	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -11.95M	$ -8.55M	$ -7.02M	$ -3.57M	$ -1.73M
Normalized Income	$ ―	$ -11.95M	$ -8.55M	$ -7.02M	$ -3.57M	$ -1.73M
Interest Expense	$ ―	$ 53.85K	$ 42.63K	$ 12.34K	$ ―	$ ―
EBIT	$ ―	$ -12.36M	$ -8.51M	$ -7.00M	$ -4.24M	$ -2.83M
EBITDA	$ ―	$ -11.77M	$ -8.03M	$ -6.73M	$ -4.24M	$ -2.83M

Currency in USD

Zelira Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing